The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Open accessAbstract
Purpose: Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss of PTEN causes deregulated phosphatidylinositol-3 kinase/serine-threonine kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling which may provide neoplastic cells with a selective survival advantage by enhancing angiogenesis, protein translation, and cell cycle progression. Temsirolimus, an ester derivative of rapamycin that inhibits mTOR, was evaluated in this setting. Patients and Methods: Sequential phase II studies evaluated single-agent activity of temsirolimus in women with recurrent or metastatic chemotherapy-naive or chemotherapy-treated endometrial cancer. Temsirolimus 25 mg intravenously was administered weekly in 4-week cycles. Results: In the chemotherapy-naive group, 33 patients received a median of four cycles (range, one to 23 cycles). Of the 29 patients evaluable for response, four (14%) had an independently confirmed partial response and 20 (69%) had stable disease as best response, with a median duration of 5.1 months (range, 3.7 to 18.4 months) and 9.7 months (range, 2.1 to 14.6 months). Only five patients (18%) had progressive disease. In the chemotherapy-treated group, 27 patients received a median of three cycles (range, one to six cycles). Of the 25 patients evaluable for response, one (4%) had an independently confirmed partial response, and 12 patients (48%) had stable disease, with a median duration of 4.3 months (range, 3.6 to 4.9 months) and 3.7 months (range, 2.4 to 23.2 months). PTEN loss (immunohistochemistry and mutational analysis) and molecular markers of PI3K/Akt/mTOR pathway did not correlate with the clinical outcome. Conclusion: mTOR inhibition with temsirolimus has encouraging single-agent activity in endometrial cancer which is higher in chemotherapy-naive patients than in chemotherapy-treated patients and is independent of PTEN status. The difference in activity according to prior therapy should be factored into future clinical trial designs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citationJemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Fleming, G. F., Brunetto, V. L., Cella, D., Look, K. Y., Reid, G. C., Munkarah, A. R., Kline, R., Burger, R. A., Goodman, A., & Burks, R. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.184 · Cited by 565
Thigpen, J. T., Brady, M. F., Alvarez, R. D., Adelson, M. D., Homesley, H. D., Manetta, A., Soper, J. T., & Given, F. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1736 · Cited by 484
Salvesen, H. B., Carter, S. L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I. M., Raeder, M. B., Sos, M. L., Engelsen, I. B., Trovik, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806514106 · Cited by 290
Risinger, J. I., Hayes, K., Maxwell, G. L., Carney, M. E., Dodge, R. K., Barrett, J. C., & Berchuck, A. (1998) · PubMed · Cited by 285
Hoskins, P. J., Swenerton, K. D., Pike, J. A., Wong, F., Lim, P., Acquino-Parsons, C., & Lee, N. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4048 · Cited by 275
Self-citationA rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214
Rose, P. G., Brunetto, V. L., VanLe, L., Bell, J., Walker, J. L., & Lee, R. B. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5865 · Cited by 199
Thigpen, T., Brady, M. F., Homesley, H. D., Soper, J. T., & Bell, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.364 · Cited by 191
Lentz, S. S., Brady, M. F., Major, F. J., Reid, G. C., & Soper, J. T. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.357 · Cited by 187
Humber, C. E., Tierney, J. F., Symonds, R. P., Collingwood, M., Kirwan, J., Williams, C., & Green, J. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl417 · Cited by 184
PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases
BUSSAGLIA, E., DELRIO, E., MATIASGUIU, X., & PRAT, J. (2000) · Human Pathology · doi:10.1016/s0046-8177(00)80244-0 · Cited by 170
Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., & Terakawa, N. (2001) · PubMed · Cited by 165
Ma, B. B. Y., Oza, A. M., Eisenhauer, E. A., Stanimir, G., Carey, M. S., Chapman, W. B., Latta, E. K., Sidhu, K., Powers, J., Walsh, W. R., et al. (2004) · International Journal of Gynecological Cancer · doi:10.1111/j.1048-891x.2004.14419.x · Cited by 159
Self-citationCatasús, L., Gallardo, A., Cuatrecasas, M., & Prat, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.5 · Cited by 122
MacKay, H. J., Gallinger, S., Tsao, M., McLachlin, C. M., Tu, D., Keiser, K., Eisenhauer, E. A., & Oza, A. M. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.031 · Cited by 83
Self-citationClinical development of mammalian target of rapamycin inhibitors
Dancey, J. E. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00051-5 · Cited by 81
Self-citationLu, K. H., Wu, W., Dave, B., Slomovitz, B. M., Burke, T. W., Munsell, M. F., Broaddus, R. R., & Walker, C. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0321 · Cited by 76
PTEN mutations and evolving concepts in endometrial neoplasia
Latta, E. K., & Chapman, W. B. (2002) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200202000-00010 · Cited by 65
Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma
Bonte, J., Ide, P. S., Billiet, G., & Wynants, P. (1981) · Gynecologic Oncology · doi:10.1016/s0090-8258(81)80003-0 · Cited by 64
AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma
Cohen, Y., Shalmon, B., Korach, J., Barshack, I., Fridman, E., & Rechavi, G. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.038 · Cited by 61
Whang, Y. E., Wu, X., & Sawyers, C. L. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.859 · Cited by 24
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole
Bellone, S., Shah, H. R., McKenney, J. K., et al. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.04.012 · Cited by 23
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Classification of endometrial carcinoma: more than two types
Murali, R., Soslow, R. A., & Weigelt, B. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70591-6 · Cited by 647
Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Koh, W.-J., Abu-Rustum, N. R., Bean, S., Bradley, K., Campos, S. M., Cho, K. R., Chon, H. S., Chu, C., Cohn, D., Crispens, M. A., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0006 · Cited by 643
Metadata
- Authors
- Oza, A. M., Elit, L., Tsao, M.-S., Kamel-Reid, S., Biagi, J., Provencher, D. M., Gotlieb, W. H., Hoskins, P. J., Ghatage, P., Tonkin, K. S., Mackay, H. J., Mazurka, J., Sederias, J., Ivy, P., Dancey, J. E., & Eisenhauer, E. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-08-20
- Volume
- 29
- Issue
- 24
- Pages
- 3278-3285
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2119607431
- Cited by
- 341
- References
- 27
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.